JGC
BBIO icon

J. Goldman & Co’s BridgeBio Pharma BBIO Stock Holding History

J. Goldman & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,750
Closed -$233K – 467
2025
Q1 		$233K Buy
+6,750
New +$228K 0.01% 432

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

J. Goldman & Co's BBIO Position: Q2 2025 in Review

J. Goldman & Co sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 6,750 shares — an estimated $233K sold.

J. Goldman & Co first reported a position in BBIO in Q1 2025 and held it in 1 quarter. The position peaked at $233K in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • J. Goldman & Co reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
  • J. Goldman & Co sold 6,750 BridgeBio Pharma shares in Q2 2025, an estimated $233K.
  • J. Goldman & Co first reported a position in BridgeBio Pharma in Q1 2025 and held it in 1 quarter.
  • J. Goldman & Co's BridgeBio Pharma position peaked at $233K in Q1 2025.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.